ReviewEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2026
Pseudomyogenic hemangioendothelioma (involving skin, bone and soft tissue): a case report with long-term follow-up and review of literature.
Review in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPseudomyogenic hemangioendothelioma is rare, usually indolent vascular tumor characterized immunohistochemically by SERPINE1-FOSB fusion, presenting as multiple bone and soft tissue lesions, affecting males in their 3rd-4th decades. CASE PRESENTATION: We present the case of a 28-years-old male patient with the history of pain in the left lower extremity hindering him in the daily activities. Radiological examinations showed well-defined lytic lesions of the femur, patella, tibia, fibula, talus and calcaneus with low metabolic activity on PET-scan. MR revealed multiple soft tissue involvements of the affected extremity. Multiple skin lesions were located on the extensor surface of the leg. Molecular analysis confirmed the pathognomonic gene fusion. Patient was treated with epirubicin as an eight-cycle locoregional intraarterial monotherapy, achieving clinical control of the disease and substantial improvement in complaints for over 10 years. The patient's complaints decreased substantially, his bony lesions, however, are persisting for over ten years of his follow-up. DISCUSSION: The molecular characteristics and differential diagnostics of the disease is well known, however, due to the rarity of the disease, the wide array of treatment methods and short-term follow-up intervals, there is still no consensus over the most efficient treatment plan. Many chemotherapeutic agents and treatment regimens were utilized throughout the literature, with acceptable outcomes as far as reported but self-limiting character and spontaneous regression of the disease have also been described according to our experience during the very long follow-up period of our patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.